注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Acorda Therapeutics Inc是一家生物制药公司。该公司致力于开发能恢复神经系统疾病患者功能和改善其生活的疗法。该公司使用其ARCUS肺部输送系统,这是一个技术平台,旨在通过吸入输送药物,用于开发各种吸入药物。该公司的产品包括INBRIJA(左旋多巴吸入粉)和AMPYRA(dalfampridine)。INBRIJA是一种吸入左旋多巴(L-dopa),用于间歇治疗间歇发作,也就是用carbidopa/左旋多巴方案治疗的帕金森病患者的间歇期。INBRIJA利用其ARCUS平台进行吸入疗法。AMPYRA(dalfampridine)是达法普利定的一种缓释片制剂,用于治疗多发性硬化症(MS)患者的步行。Ampyra由Biogen International GmbH在美国境外以“Fampyra”的名义销售。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Ron Cohen | 67 | 1995 | Founder, CEO, President & Director |
Sandra Panem | 76 | 1998 | Independent Director |
John P. Kelley | 69 | 2008 | Independent Non-Executive Chairman |
Michael S. Beattie | - | - | Member of Scientific Advisory Board |
Mark Tuszynski | - | - | Member of Scientific Advisory Board |
Melitta Schachner | - | - | Member of Scientific Advisory Board |
Carl W. Cotman | 83 | - | Member of Scientific Advisory Board |
Jerry Silver | - | - | Member of Scientific Advisory Board |
Jacqueline C. Bresnahan | - | - | Member of Scientific Advisory Board |
James W. Fawcett | - | - | Member of Scientific Advisory Board |
Eugene M. Johnson | - | - | Member of Scientific Advisory Board |
Mary B. Bunge | - | - | Member of Scientific Advisory Board |
Stephen G. Waxman | - | - | Member of Scientific Advisory Board |
Patrick A. Tresco | - | - | Member of Scientific Advisory Board |
Peder K. Jensen | 68 | 2011 | Independent Director |
John W. Varian | 63 | 2022 | Independent Director |
Thomas M. Burns | 49 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核